P A Evrard1, G Deridder, R K Verbeeck. 1. Pharmacokinetics Laboratory, School of Pharmacy, Catholic University of Louvain, Brussels, Belgium.
Abstract
PURPOSE: A flexible microdialysis probe was designed for intravenous sampling in small laboratory animals. METHODS: Surgical techniques were developed to implant this probe via the femoral vein in the vena cava of the mouse and the rat. The in- and outlet of the probe were exteriorized above the tail of the animal and were directly connected to the microsyringe pump for perfusate delivery and to the injection valve for on-line HPLC analysis of the microdialysate samples. RESULTS: The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively. The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen. The pharmacokinetics of unbound flurbiprofen were studied following i.v. bolus administration of flurbiprofen to the mouse (n = 4) and the rat (n = 6) with on-line HPLC analysis of microdialysates to unbound concentrations using the in vivo loss of flurbiprofen by retrodialysis carried out just before the start of the pharmacokinetic experiment. The integrity of the probe throughout the experiment was monitored by continuous retrodialysis of naproxen. CONCLUSIONS: The developed techniques can be used to carry out routine pharmacokinetic studies in the mouse and the rat illustrated by our experiments with flurbiprofen, a compound with very high plasma protein binding.
PURPOSE: A flexible microdialysis probe was designed for intravenous sampling in small laboratory animals. METHODS: Surgical techniques were developed to implant this probe via the femoral vein in the vena cava of the mouse and the rat. The in- and outlet of the probe were exteriorized above the tail of the animal and were directly connected to the microsyringe pump for perfusate delivery and to the injection valve for on-line HPLC analysis of the microdialysate samples. RESULTS: The in vitro recoveries of flurbiprofen and naproxen for these probes were 68.2 +/- 6.9% (mean +/- S.D., n = 12) and 66.5 +/- 7.3%, respectively. The relatively loss by in vivo retrodialysis, measured the day after the implantation of the probes, was 66.1 +/- 8.8% for flurbiprofen and 60.9 +/- 9.9% for naproxen. The pharmacokinetics of unbound flurbiprofen were studied following i.v. bolus administration of flurbiprofen to the mouse (n = 4) and the rat (n = 6) with on-line HPLC analysis of microdialysates to unbound concentrations using the in vivo loss of flurbiprofen by retrodialysis carried out just before the start of the pharmacokinetic experiment. The integrity of the probe throughout the experiment was monitored by continuous retrodialysis of naproxen. CONCLUSIONS: The developed techniques can be used to carry out routine pharmacokinetic studies in the mouse and the rat illustrated by our experiments with flurbiprofen, a compound with very high plasma protein binding.